Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
Significantly more patients had 18-month event-free survival in nivolumab versus chemotherapy group
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.